19th Sep 2014 08:17
LONDON (Alliance News) - ANGLE PLC Friday said it has signed a collaboration agreement with the Norris Comprehensive Cancer Center at the University of Southern California under which the pair will investigate the clinical use of the Parsortix cell separation system for breast cancer.
The team working on the project will seek to evaluate if circulating tumour cells, or CTCs, can be successfully isolated and profiled from Stage 4 breast cancer patients, with or without background subtraction of contaminating leukocytes.
It will also consider if CTCs may serve as a surrogate for biopsies of macrometastases by paired comparisons for each patient and it will study if profiling CTCs' biology sequentially over time may explain treatment resistance to HER2 directed therapy, chemotherapy, or endocrine therapy, and further identify novel treatment targets.
"We hope that, using the Parsortix system to harvest CTCs, Dr Lang and her team may be able to develop new approaches which replace invasive biopsies of secondary cancers with non-invasive blood tests and improve the overall outcome for breast cancer patients in the future," said ANGLE Chief Executive Andrew Newland.
Shares in ANGLE were Friday trading 0.85% higher at 89.00 pence per share.
By Sam Unsted; [email protected]; @SamUAtAlliance
Copyright 2014 Alliance News Limited. All Rights Reserved.
Related Shares:
Angle